Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...
STAT11d
Eli Lilly says modified dosing of its Alzheimer’s drug may be safer
A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...
GlobalData on MSN10d
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related ...
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high ...
Nasdaq11d
Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients
In these patients, 19% had ARIA-E on the modified titration as compared to 57% on the standard dosing regimen, resulting in a 67% lower relative risk. Lilly is discussing the results of this study ...
Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients
Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...